-
Mashup Score: 0Reacting to the FDA Approval of Fluticasone Propionate Nasal Spray, with James Palmer, MD - 23 hour(s) ago
James Palmer, MD, provides perspective on the FDA’s decision to approve fluticasone propionate nasal spray for adults with chronic rhinosinusitis without nasal polyps.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4FDA Warns of T-Cell Malignancy Risk in CAR-T Immunotherapies | ASH Clinical News | American Society of Hematology - 4 day(s) ago
The U.S. Food and Drug Administration (FDA) issued a warning about the risk of T-cell malignancies in patients who have received BCMA- or CD19-directed autologous chimeric antigen receptor (CAR) T-cell immunotherapies. The warning followed the receipt of reports from clinical trials and post-marketing adverse event sources detailing T-cell malignancy occurrences in this patient population. A press release from the FDA noted that the benefits of these therapies still outweigh this risk, but the need for
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Matthew J. Frigault, MD, MS, discussed what a community oncologist should know about the ongoing FDA investigation of chimeric antigen receptor T-cell therapies.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Following changes to the manufacturing process, the phase 1 study of NX-2127 in B-cell malignancies has been cleared to continue by the FDA.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
The combination of zanubrutinib and obinutuzumab is now an approved treatment option for adult patients with relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
The combination of zanubrutinib and obinutuzumab is now an approved treatment option for adult patients with relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Olaptesed Pegol Gains FDA Clearance in Glioblastoma - 12 day(s) ago
The FDA approved the investigational new drug application for olaptesed pegol as a potential treatment for adult patients with aggressive brain cancer, specifically glioblastoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6FDA Approves Inotuzumab for Pediatric Patients with ALL - 12 day(s) ago
The FDA has approved inotuzumab for the treatment of pediatric patients aged 1 year or older with acute lymphoblastic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The novel cell therapy A2B530 is the first logic-gated cell therapy aimed at selectively killing tumor cells and protecting healthy cells in colorectal cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
In a recent interview, Dr. James Palmer provided perspective on the #FDA decision to approve fluticasone propionate nasal spray for adults with chronic rhinosinusitis without nasal polyps. View the interview/summary here: https://t.co/ufzhqHMuWu